Table III.
Summary matrix of patient samples (NCM) treated with selected compound(s).
| Sample ID | WHO category | #1 |
#26 |
#30 |
#36 |
#37 |
#38 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TM | PM | TM | PM | TM | PM | TM | PM | TM | PM | TM | PM | ||
| Decreasing total motility | |||||||||||||
| 721 | WHO normal | ↓ | ↓ | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― |
| 710 | WHO normal | ― | ― | ↑ | ― | ↑ | ― | ― | ↓ | ↑ | ― | ↑ | ― |
| 716 | WHO normal | ― | ↑ | ― | ↑ | ― | ↑ | ― | ↑ | ― | ↑ | ― | ↑ |
| 663 | WHO normal | ― | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 734 | WHO normal | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ||
| 736 | WHO normal | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ||
| 774 | WHO normal | ― | ↑ | ― | ↑ | ― | ↑ | ― | ― | ― | ↑ | ― | ↑ |
| 717 | WHO normal | ― | ― | ― | ↑ | ― | ↑ | ― | ↑ | ― | ― | ― | ― |
| 557 | Borderline | ↑ | ― | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| PT01 | Borderline | ― | ↑ | ↑ | ↑ | ― | ↑ | ||||||
| 723 | Borderline | ― | ↑ | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ||||
| 784 | Borderline | ― | ↑ | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ↑ | ↑ | ― | ↑ |
| 786 | Borderline | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ↑ | ↑ | ↑ | ↑ |
| 642 | Borderline | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||
| 653 | Borderline | ― | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 769 | Borderline | ― | ― | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ― | ↑ | ― | ↑ |
| 760 | Low TM and PM | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― |
| 782 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ||||||
| 708 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 725 | Low TM and PM | ― | ― | ↑ | ― | ― | ― | ― | ― | ↑ | ― | ↑ | ― |
| 709 | Low TM and PM | ↑ | ↑ | ||||||||||
| 761 | Low TM and PM | ↑ | ↑ | ||||||||||
| 729 | Low TM and PM | ↑ | ↑ | ||||||||||
↑, Significant increase; —, no change; ↓, significant decrease; empty cell, drug was not used in the experiment.WHO normal: WHO normal limits for total motility (40%) and progressive motility (32%), Borderline: borderline motility, low TM and low PM: both total and progressive motility are below the WHO normal limit. No entry means compound is not tested. Significance means SD do not overlap (TM: total motility, PM: progressive motility).